Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dose-dense FEC75 vs FEC90 in early breast cancer
NCT00286819Phase 2Completed
- Sponsor
- Central European Cooperative Oncology Group
- Start
- Apr 2005
- Modality
- DNA Intercalators/Alkylators
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of epirubicin in breast cancer, sponsored by Central European Cooperative Oncology Group. Started Apr 2005; status: completed.
02
Drugs
epirubicin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT00286819.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00286819.